SCHEMBL23926346

SCHEMBL23926346

CCN(CC)CCCc1cccc(C=O)c1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 4/20 0.42
TLR2 O60603 1/20 0.41
TLR1 Q15399 1/20 0.41
TLR6 Q9Y2C9 1/20 0.41
HTR1A P08908 2/20 0.39
CHRM2 P08172 1/20 0.39
ADRA2A P08913 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD1 P21728 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
OPRM1 P35372 1/20 0.39
DRD3 P35462 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
SCN1A P35498 1/20 0.37
SCN2A Q99250 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30118933 1.00 ERN1 (0.42) ERN1TLR2TLR1TLR6HTR1A
SCHEMBL30118893 0.91 ERN1 (0.44) ERN1TLR2TLR1TLR6HTR1A
SCHEMBL23926336 0.91 ERN1 (0.44) ERN1TLR2TLR1TLR6HTR1A
SCHEMBL9915272 0.90 ALOX5 (0.42) ERN1TLR2TLR1TLR6HTR1A
SCHEMBL193427 0.83 ALOX5 (0.49) ERN1TLR2TLR1TLR6GABRA1
SCHEMBL1527091 0.81 ALOX5 (0.55) ERN1TLR2TLR1TLR6ALOX5
SCHEMBL8531468 0.80 ALOX5 (0.54) ERN1ALOX5PTGS2
SCHEMBL11503688 0.80 ALOX5 (0.54) ERN1ALOX5PTGS2
SCHEMBL6910210 0.80 ALOX5 (0.54) ERN1ALOX5PTGS2
SCHEMBL7091232 0.80 ALOX5 (0.46) ERN1TLR2TLR1TLR6GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 ERN1 3580/4885TLR2 4740/4885TLR1 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.